The GOLGA7 knockout Jurkat polyclonal cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for investigating Golgi biology in a human T-lymphocyte context. This loss-of-function model is generated by targeted disruption of the GOLGA7 gene via CRISPR/Cas9 technology, resulting in a heterogeneous pool of Jurkat cells with altered GOLGA7 expression. Unlike clonal knockout cell lines, this polyclonal population preserves genetic diversity while providing robust functional ablation of the encoded protein, enabling bulk-population assays relevant to cellular trafficking and signaling studies.
The host cell line, Jurkat, is an immortalized human T-cell leukemia line originally derived from the peripheral blood of a 14-year-old male patient. These cells are widely employed as a model for T-cell receptor (TCR) signaling, activation, and apoptosis. Their rapid proliferation and well-characterized signaling pathways make them particularly suitable for studying the intersection of membrane trafficking and immune receptor function. In this system, GOLGA7 disruption offers a targeted approach to dissect the contributions of the Golgi apparatus to leukocyte biology.
GOLGA7 encodes a coiled-coil protein localized to the cis-Golgi network, where it functions as a tethering factor essential for Golgi stack maintenance and intra-Golgi vesicle transport. Mechanistically, GOLGA7 forms complexes with GM130 (GOLGA2), p115 (USO1), and the COPI coatomer, acting downstream of ARF1 GTPase to mediate vesicle docking. It is activated upstream by mitogenic stimuli and TCR activation signals, regulating downstream processes such as Golgi morphology, protein glycosylation, secretion efficiency, and surface receptor expression. These interactions place GOLGA7 at a central node in the cis-Golgi matrix, coordinating COPI-dependent retrograde transport and overall Golgi ribbon integrity.
In Jurkat T cells, knockout of GOLGA7 disrupts Golgi architecture, leading to impaired protein trafficking and aberrant glycosylation patterns. This dysfunction can alter the surface levels and signaling competency of critical TCR components such as CD3 and CD28, potentially affecting downstream cytokine secretion (e.g., IL-2) and apoptotic responses. Consequently, this polyclonal knockout model is uniquely suited to explore the role of Golgi organization in T-cell activation, malignant transformation, and the pathogenesis of Golgi-linked disorders, including context-dependent contributions to T-cell acute lymphoblastic leukemia.
Researchers can apply this product to a diverse range of investigations, including mechanistic studies of Golgi structure-function relationships, protein trafficking in leukocytes, and the impact of Golgi disruption on immune signaling. Representative assays include immunofluorescence staining of Golgi markers (GM130, TGN46), immunoblotting for GOLGA7 and glycosylation status, flow cytometric analysis of surface receptors (CD3, CD28), and functional readouts such as IL-2 secretion, apoptosis, and proliferation assays. Ultrastructural analysis by electron microscopy further enables detailed visualization of Golgi morphology changes. For additional technical specifications or experimental guidance, please contact Ascent Research.
